ENANTA PHARMACEUTICALS INC (ENTA)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Total revenue | 18,314 | 14,926 | ||
| Research and development | 27,210 | 28,065 | ||
| General and administrative | 9,997 | 11,388 | ||
| Total operating expenses | 37,207 | 39,453 | ||
| Loss from operations | -18,893 | -24,527 | ||
| Interest and investment income, net | 2,285 | 2,292 | ||
| Interest expense | 1,618 | 1,714 | ||
| Total other income, net | 667 | 578 | ||
| Loss before income taxes | -18,226 | -23,949 | ||
| Income tax (expense) benefit | 29 | -1,305 | ||
| Net loss | -18,255 | -22,644 | ||
| Basic | 21,377,000 | 21,355,000 | ||
| Earnings per share, basic | -0.85 | -1.06 | ||
| Earnings per share, diluted | -0.85 | -1.06 | ||
| Weighted average number of shares outstanding, diluted | 21,377,000 | 21,355,000 | ||